

Molecular classification of diffuse large B-Cell lymphoma and novel treatment strategies

Daisuke Ennishi

Okayama University Hospital, Japan

Diffuse large cell lymphoma (DLBCL) represents a largest number of entities among lymphoid cancers, which are an aggregate of clinically and biologically diverse diseases. In particular, it is thought that various molecular genetic abnormalities are involved in the tumorigenesis of disease development. Due to recent advances in multi-omics analyses, gene expression profile reflecting cell-of-origin and tumor microenvironment, and recurrent genetic abnormalities have been discovered, which is important aspect for the development of future new therapeutic drugs and indications for clinical trials, ultimately leading to the precision medicine in the area of DLBCL.